Recently, several repurposing drugs have been identified that specifically inhibit ACSL4, such as Abemaciclib and PRGL493, but their potential role and/or side effects in ferroptotic-related diseases, especially in acute or chronic kidney diseases, remain to be further investigated58,59. The gene discussed is ACSL4; the disease is glycogen storage disease VI.